The Expression of Interleukin-1β and NLRP3 Inflammasome Components in Hidradenitis Suppurativa Lesional Skin
Sneha Shrotri, Andrea R. Daamen, Mittie K. Doyle, Inbal Zafir-Lavie, Peter E. Lipsky, JID Innovations, 2026, 100532.
View article
Efficacy and Safety of Abdakibart, a Selective Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa; Primary Results of the Placebo-Controlled Phase 2 LOTUS Trial
Presented at: European Academy of Dermatology and Venereology (EADV) 2026 Congress, Vienna Austria
View Poster
Efficacy and Safety of Abdakibart (ABD), a Humanized High Affinity and Potency IgG4 Anti-IL-1β Agent for Treatment of Moderate to Severe Hidradenitis Suppurativa at Week 16; IHS4 Subgroup and Lesion Type ANdT Results of the Phase 2 Placebo Controlled LOTUS Trial
Presented at: European Academy of Dermatology and Venereology (EADV) 2026 Congress, Vienna Austria
View Presentation